Finally, we demonstrated that the patients who tested negative for the anti-PF4/heparin antibody and who also exhibited a thrombocytopenia or underwent administration of antiplatelet drugs were at significantly increased risk for clinical bleeding. The gene discussed is PF4; the disease is Thrombocytopenia.